In my cart

You have no items in your shopping cart.


Product overview

  • Name
    XAV 939
  • Short description
    Potent tankyrase inhibitor. Wnt/β-catenin signaling inhibitor.
  • Biological description

    XAV 939 is a potent tankyrase (TNKS) inhibitor (IC50 values are 4 and 11 nM at TNKS2 and TNKS1 respectively). Recently it has been indicated that XAV 939 also inhibits multiple PARP family proteins.

    XAV 939 antagonizes Wnt signaling by stabilizing axin to stimulate β-catenin degradation.

    XAV 939 also displays antiproliferative and apoptotic inducing properties.

    XAV 939 robustly induces cardiomyogenesis in mouse embryonic stem (ES) cells.

  • Biological action
  • Purity
  • Citations


  • Chemical name
  • Molecular Weight
  • Chemical structure
    XAV 939  [284028-89-3]
  • Molecular Formula
  • CAS Number
  • PubChem identifier
  • Source
  • InChi
  • InChiKey
  • MDL number

Storing and Using Your Product

  • Storage instructions
    Room temperature
  • Solubility overview
    Soluble in DMSO (20mM)
  • Important
    This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

References for XAV 939

  • XAV939 inhibits the stemness and migration of neuroblastoma cancer stem cells via repression of tankyrase 1.

    Tian X et al (2014) Int J Oncol 45(1) : 121-8.
    PubMedID: 24789807
  • Modelling of a targeted nanotherapeutic 'stroma' to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt-β-catenin signalling, for use in human fetal dopaminergic grafts in Parkinson's disease.

    Zhao JW et al (2014) Dis Model Mech 7(10) : 1193-203.
    PubMedID: 25085990
  • Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939.

    Kirby CA et al (2012) Acta Crystallogr Sect F Struct Biol Cryst Commun 68(Pt 2) : 115-8.
    PubMedID: 22297980
  • XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway.

    Tian XH et al (2013) J Exp Clin Cancer Res 32 : 100
    PubMedID: 24308762
Support & Resources